---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021862"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:44:02.762997+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports Q3 net loss $17.7M; cash $344.2M; DT-216 Phase 1 SAD data in Dec 2022

## Summary
- Net loss of $17.7M for Q3 2022; R&D expenses $14.3M, G&A expenses $4.9M.
- Cash, equivalents and securities of $344.2M as of Sept 30, 2022, supporting multi-year runway.
- Initial data from DT-216 single-ascending dose Phase 1 for Friedreich Ataxia expected Dec 2022.
- Multiple-ascending dose Phase 1 dosing initiated; completion anticipated mid-2023.
- DM1 GeneTAC program preclinical; clinical development expected to begin in 2023.

## SEC filing metadata
- accession: 0000950170-22-021862
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017022021862/0000950170-22-021862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017022021862/dsgn-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021862
- JSON: https://secwatch.observer/filing/0000950170-22-021862.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021862.txt

## Key facts
- Earnings Releases
  Design Therapeutics, Inc. reported third quarter 2022 results: net income Net loss was $17.7 million.
  - Period: third quarter 2022
  - Net income: Net loss was $17.7 million
  - Result: reported results
  source text: Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017022021862/0000950170-22-021862-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.